News

Webcast Image Webcast
IRIDEX Corporation at the Lytham Partners Fall 2021 Investor Conference
10/07/21 at 11:45 AM EDT

Webcast Image Webcast
Q3 2021 IRIDEX Earnings Conference Call
11/11/21 at 5:00 PM EST

Webcast Image Webcast
Stifel 2021 Virtual Healthcare Conference
11/16/21 at 2:00 PM EST

Date Title Teaser
11/12/21
Summary ToggleIridex to Present at the 2021 Stifel Virtual Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 2021 Stifel Virtual
11/11/21
Summary ToggleIridex Announces Third Quarter 2021 Financial Results Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance MOUNTAIN VIEW, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 2, 2021 . Third Quarter Highlights Revenue of $13.3 million ,
11/06/21
Summary ToggleRetina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021 Panel members scheduled for discussions at the Iridex booth during AAO meeting on November 13-15th MOUNTAIN VIEW, Calif. , Nov.
10/28/21
Summary ToggleIridex to Report Third Quarter 2021 Financial Results on November 11, 2021 MOUNTAIN VIEW, Calif. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021
09/30/21
Summary ToggleIridex to Present at the Lytham Partners Fall 2021 Investor Conference MOUNTAIN VIEW, Calif. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming Lytham Partners Fall
08/12/21
Summary ToggleIridex Announces Second Quarter 2021 Financial Results Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance MOUNTAIN VIEW, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 3, 2021 .
08/09/21
Summary ToggleIridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference MOUNTAIN VIEW, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C.
07/29/21
Summary ToggleIridex to Report Second Quarter 2021 Financial Results on August 12, 2021 MOUNTAIN VIEW, Calif. , July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of
05/11/21
Summary ToggleIridex Announces First Quarter 2021 Financial Results MOUNTAIN VIEW, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021 . First Quarter Highlights Closed strategic collaboration with Topcon Corporation netting $19.5 million in new funds Record first
04/27/21
Summary ToggleIridex to Report First Quarter 2021 Financial Results on May 11, 2021 MOUNTAIN VIEW, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of
03/22/21
Summary ToggleIridex Announces Fourth Quarter and Full Year 2020 Financial Results MOUNTAIN VIEW, Calif. , March 22, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021 . Fourth Quarter Highlights Total revenue in the fourth quarter increased 5% to $12.3 million year-over-year Sold
03/10/21
Summary ToggleIridex Completes Transaction with Topcon Corporation MOUNTAIN VIEW, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with Topcon
03/08/21
Summary ToggleIridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021 MOUNTAIN VIEW, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and
03/02/21
Summary ToggleIridex Announces Strategic Collaboration with Topcon Corporation Transaction provides $19.5 million cash to Iridex , as two leaders join forces in glaucoma and  retinal disease treatment Iridex to host a conference call presentation on March 2, 2021 at 2:00 p.m. PT / 5:00 p.m. ET MOUNTAIN VIEW, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation
01/11/21
Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020 MOUNTAIN VIEW, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 2, 2021 . Fourth Quarter 2020 Total revenue expected to be $12.2 million to $12.4
logo aa0 logo ags logo ascrs logo asrs logo esrs0 logo euretina